1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (310) 998-3965
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma†
A randomized, double-blind, multicenter, comparative trial
Article first published online: 29 AUG 2003
DOI: 10.1002/cncr.11701
Copyright © 2003 American Cancer Society
Additional Information
How to Cite
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., Chen, B.-L. and Seaman, J. J. (2003), Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer, 98: 1735–1744. doi: 10.1002/cncr.11701
- †
Performed on behalf of the Zoledronic Acid Breast Cancer and Multiple Myeloma Study Group
Publication History
- Issue published online: 3 OCT 2003
- Article first published online: 29 AUG 2003
- Manuscript Accepted: 14 JUL 2003
- Manuscript Revised: 23 JUN 2003
- Manuscript Received: 5 MAR 2003
Funded by
- Novartis Pharmaceuticals Corporation (East Hanover, New Jersey)
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations, Cancer Treatment Reviews, 2012,
- 2, , Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers, Journal of Medical Economics, 2012, 15, 1, 185
- 3, , Biochemical-markers for the diagnosis of bone metastasis: A clinical review, Cancer Epidemiology, 2012, 36, 1, 94
- 4
- 5, , Bone health management in patients with breast cancer: Current standards and emerging strategies, The Breast, 2012, 21, 1, 8
- 6
- 7, , , , , , , , , , Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy, Leukemia & Lymphoma, 2012, 53, 6, 1057
- 8, , , , , , , , Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective, Journal of Medical Economics, 2012, 15, 3, 454
- 9, Denosumab for the management of bone disease in patients with solid tumors, Expert Review of Anticancer Therapy, 2012, 12, 3, 307
- 10, , , Diagnosis and Management of Metastatic Cervical Spine Tumors, Orthopedic Clinics of North America, 2012, 43, 1, 75
- 11
- 12, , , Evaluation of the Clinical Benefit of Long-term (Beyond 2 Years) Treatment of Skeletal-Related Events in Advanced Cancers With Zoledronic Acid, Current Medical Research and Opinion, 2012, 1
- 13, , , Evidence for Using Bisphosphonate to Treat Legg-Calvé-Perthes Disease, Clinical Orthopaedics and Related Research®, 2012,
- 14
- 15, , , , Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma, American Journal of Hematology, 2012, 87, 5Direct Link:
- 16, , , Progress in the treatment of bone metastases in cancer patients, Expert Opinion on Investigational Drugs, 2012, 21, 6, 785
- 17, , , , , , , , Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis, The Breast, 2012,
- 18, , Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan, Journal of Medical Economics, 2012, 15, 1, 175
- 19, , , Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases, Journal of Medical Economics, 2012, 15, 1, 195
- 20, , , , , , , , , , , , Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases, Journal of Oral and Maxillofacial Surgery, 2012,
- 21, , Skeletal metastasis in renal cell carcinoma: Current and future management options, Cancer Treatment Reviews, 2012, 38, 4, 284
- 22, , , , , , , , Taking the lead – Sharing best practice in intravenous bisphosphonate use in urological cancers, European Journal of Oncology Nursing, 2012, 16, 1, 42
- 23, The Medical Research Council Myeloma IX Trial: New Clinical Insights on the Anticancer Effects of Zoledronic Acid in Patients With Multiple Myeloma, Clinical Lymphoma Myeloma and Leukemia, 2012, 12, 1, 2
- 24, , , , , Therapeutic approaches to myeloma bone disease: An evolving story, Cancer Treatment Reviews, 2012,
- 25, , , , , Treatment of bone metastases before the onset of pain, International Journal of Clinical Oncology, 2012,
- 26
- 27
- 28
- 29, , , Adverse effects of bisphosphonates, ReumatologÃa ClÃnica (English Edition), 2011, 7, 3, 189
- 30, , Assessment and Management of Pain in the Terminally Ill, Primary Care: Clinics in Office Practice, 2011, 38, 2, 195
- 31
- 32, , Breast cancer at bone metastatic sites: recent discoveries and treatment targets, Journal of Cell Communication and Signaling, 2011, 5, 2, 85
- 33, , , , , , , , Comparison of Skeletal Complications and Treatment Patterns Associated With Early vs. Delayed Zoledronic Acid Therapy in Multiple Myeloma, Clinical Lymphoma Myeloma and Leukemia, 2011, 11, 4, 326
- 34, , , , , , , , , , , , , , Consensus on the utility of bone markers in the malignant bone disease setting, Critical Reviews in Oncology/Hematology, 2011, 80, 3, 411
- 35, Current status of bone-targeted therapy for cancer patients, Community Oncology, 2011, 8, 8, 26
- 36, , De la evidencia a la recomendación: una tarea pendiente, Medicina ClÃnica, 2011, 136, 13, 601
- 37, , , , Direct antitumour activity of zoledronic acid: preclinical and clinical data, Clinical and Translational Oncology, 2011, 13, 3, 148
- 38, , Dose-dependent differential effects of risedronate on gene expression in osteoblasts, Biochemical Pharmacology, 2011, 81, 8, 1036
- 39, , , , , Dosing of zoledronic acid throughout the treatment continuum in breast cancer, Critical Reviews in Oncology/Hematology, 2011, 79, 2, 175
- 40
- 41, , , , , , , , , , , , , , , , , , , Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial, The Lancet Oncology, 2011, 12, 8, 743
- 42, , , , Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I–II study, Oral Oncology, 2011, 47, 3, 185
- 43, , , Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease, Critical Reviews in Oncology/Hematology, 2011, 77, S13
- 44, , , , , , , , , , , , , , , , , , , , , , Guide de recommandations d’utilisation des bisphosphonates dans les lésions osseuses malignes des tumeurs solides et du myélome multiple, La Revue de Médecine Interne, 2011, 32, 8, 494
- You have free access to this content45, , , , , , , , , , , , , , Guidelines for the diagnosis and management of multiple myeloma 2011, British Journal of Haematology, 2011, 154, 1Direct Link:
- 46, , , , , , , , , , , , , , Hospital Resource Utilization and Treatment Cost of Skeletal-Related Events in Patients with Metastatic Breast or Prostate Cancer: Estimation for the Portuguese National Health System, Value in Health, 2011, 14, 4, 499
- 47, , , , , , , , Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience, Annals of Oncology, 2011, 23, 1, 193
- 48, Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates, Expert Opinion on Pharmacotherapy, 2011, 12, 5, 749
- 49, , Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications, Cancer Immunology, Immunotherapy, 2011, 60, 3, 305
- 50, Managing bone health with zoledronic acid: a review of randomized clinical study results, Climacteric, 2011, 14, 3, 321
- 51, , , , , , , , , , Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006, Breast Cancer Research and Treatment, 2011, 131, 1, 231
- 52, New developments for treatment and prevention of bone metastases, Current Opinion in Oncology, 2011, 23, 4, 338
- 53, , , New role for an established drug? Bisphosphonates as potential anticancer agents, Prostate Cancer and Prostatic Diseases, 2011, 15, 2, 111
- 54, , , , Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists, Supportive Care in Cancer, 2011, 19, 11, 1687
- 55, , , , , , , , , , , , , , , , Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study, Leukemia & Lymphoma, 2011, 52, 5, 771
- 56, , , , , , , , , , Pharmacokinetic evaluation of zoledronic acid, Expert Opinion on Drug Metabolism & Toxicology, 2011, 7, 7, 911
- 57, , , , , Preventive Effects of Zoledronic Acid on Bone Metastasis in Mice Injected with Human Breast Cancer Cells, Journal of Korean Medical Science, 2011, 26, 12, 1569
- 58, , , , , , , , , , , , , , , , , , , Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid, American Journal of Hematology, 2011, 86, 1Direct Link:
- 59, , , , Prognostic Significance of Bone Markers in Patients With Lung Cancer Metastatic to the Skeleton: A Review of Published Data, Clinical Lung Cancer, 2011, 12, 6, 341
- 60, , , , , , , , Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial), The Journal of Supportive Oncology, 2011, 9, 1, 32
- 61, , , , , Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid, Supportive Care in Cancer, 2011, 20, 1, 87
- 62, , , The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer, Breast Cancer Research and Treatment, 2011, 132, 2, 355
- 63, The use of bisphosphonates in cancer treatment, Annals of the New York Academy of Sciences, 2011, 1218, 1Direct Link:
- 64, , , Treatment and prevention of bone complications from prostate cancer, Bone, 2011, 48, 1, 88
- 65, , , Zoledronic acid for adjuvant use in patients with breast cancer, Expert Review of Anticancer Therapy, 2011, 11, 3, 333
- 66, , , , , Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma, Thyroid, 2011, 21, 1, 31
- 67, , , , , Zoledronic acid use in cancer patients, Cancer, 2011, 117, 1Direct Link:
- 68, Zoledronic acid: multiplicity of use across the cancer continuum, Expert Review of Anticancer Therapy, 2011, 11, 7, 1001
- 69
- 70
- 71, , , , , , A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer, International Journal of Clinical Oncology, 2010, 15, 4, 382
- 72, , , Atrial fibrillation and bisphosphonate therapy, Journal of Bone and Mineral Research, 2010, 25, 1Direct Link:
- 73, , , , , Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: A word of caution for oral surgeons and oncologists, European Journal of Surgical Oncology (EJSO), 2010, 36, 6, 541
- 74, , , , , , , Bisphosphonate-Induced Osteonecrosis of the Jaw 32 Months After Interruption of Zoledronate in a Patient With Multiple Myeloma, Journal of Oral and Maxillofacial Surgery, 2010, 68, 5, 1179
- 75, , , , , Bisphosphonate-related osteonecrosis of the jaws: How to manage cancer patients, Oral Oncology, 2010, 46, 6, 468
- 76, Bisphosphonates: ready for use as adjuvant therapy of breast cancer?, Current Opinion in Obstetrics and Gynecology, 2010, 22, 1, 61
- 77, , Bone Disease in Breast Cancer: The Era of New Targeted Therapies, Current Breast Cancer Reports, 2010, 2, 1, 25
- 78, , , , , , , Bone pain reduction in patients with metastatic breast cancer treated with ibandronate–results from a post-marketing surveillance study, Supportive Care in Cancer, 2010, 18, 10, 1305
- 79, , Bone-marker levels in patients with prostate cancer: potential correlations with outcomes, Current Opinion in Supportive and Palliative Care, 2010, 4, 3, 127
- 80, , , Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer, Clinical Genitourinary Cancer, 2010, 8, 1, 29
- 81, , , , , , Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom, The European Journal of Health Economics, 2010, 12, 6, 575
- 82, , , Disease Progression Increases the Risk of Skeletal-Related Events in Patients With Bone Metastases From Castration-Resistant Prostate Cancer, Lung Cancer, or Other Solid Tumors, Cancer Investigation, 2010, 28, 8, 849
- 83, , , , , , , , , , , , , , , , , , , , , , Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial, The Lancet Oncology, 2010, 11, 10, 973
- 84, , , , , , Effect of pamidronate infusion time on renal function in patients with multiple myeloma, Farmacia Hospitalaria (English Edition), 2010, 34, 1, 23
- You have free access to this content85, , , , Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma, British Journal of Haematology, 2010, 151, 1Direct Link:
- 86, , , , , , , , , , , , , , , , , , First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial, The Lancet, 2010, 376, 9757, 1989
- 87, Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy, Seminars in Oncology, 2010, 37, S15
- 88, , , , , , Influencia del tiempo de perfusión de pamidronato en la función renal de pacientes con mieloma múltiple, Farmacia Hospitalaria, 2010, 34, 1, 23
- 89, , , , , , , , , , , , , , , Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo, Journal of Bone and Mineral Research, 2010, 25, 12Direct Link:
- 90, , , , , , , , , Intravenous Bisphosphonate Therapy Does Not Acutely Alter Nuclear Bone Scan Results, Clinical Breast Cancer, 2010, 10, 1, 33
- 91, , Intravenous pamidronate for myeloma bone disease: can the dose be lowered?, The Lancet Oncology, 2010, 11, 10, 913
- 92, , , , , , , , Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid, Translational Research, 2010, 155, 5, 247
- 93
- 94, , , , Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review, Nature Reviews Endocrinology, 2010, 7, 1, 34
- 95, , , Pharmacologic Prevention of Skeletal-Related Events in Cancer Patients, Orthopedics, 2010, 33, 8, 577
- 96, , , , , , , , , , , , Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study, Lung Cancer, 2010, 67, 1, 114
- 97, , , , , , Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates, Cancer Chemotherapy and Pharmacology, 2010, 67, 5, 1137
- 98, , , , , Prognostic factors for skeletal complications from metastatic bone disease in breast cancer, Breast Cancer Research and Treatment, 2010, 123, 3, 767
- 99, , , , , Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease, Leukemia, 2010, 24, 5, 1043
- 100, , , , , Risk Factors Contributing to the Development of Hypocalcemia after Zoledronic Acid Administration in Patients with Bone Metastases of Solid Tumor, Biological & Pharmaceutical Bulletin, 2010, 33, 4, 721
- 101, , Safety Considerations for Use of Bone-Targeted Agents in Patients With Cancer, Seminars in Oncology, 2010, 37, S66
- 102, , Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates, Lung Cancer, 2010, 67, 1, 4
- 103
- 104, , Systemic Metabolic Radiopharmaceutical Therapy in the Treatment of Metastatic Bone Pain, Seminars in Nuclear Medicine, 2010, 40, 2, 89
- 105, , , , , , The Current Status and Future of Multiple Myeloma in the Clinic, Clinical Lymphoma, Myeloma & Leukemia, 2010, 10, 1, E1
- 106, , , , , , The Current Status and Future of Multiple Myeloma in the Clinic, Clinical Lymphoma, Myeloma & Leukemia, 2010, 10, 1, 28
- 107, Therapeutic Options in the Management of Myeloma Bone Disease, Seminars in Oncology, 2010, 37, S20
- 108, , , , , , , , , , , , , , , , Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en HematologÃa, Medicina ClÃnica, 2010, 134, 6, 268
- 109, , , , , , , , , , , , Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma, Hepatology Research, 2010, 40, 12Direct Link:
- 110, , Zoledronic Acid Improves Clinical Outcomes When Administered Before Onset of Bone Pain in Patients With Prostate Cancer, Urology, 2010, 76, 5, 1175
- 111, , , , , Are bisphosphonates the suitable anticancer drugs for the elderly?, Critical Reviews in Oncology/Hematology, 2009, 69, 1, 83
- 112, , , Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies, Osteoporosis International, 2009, 21, 4, 705
- 113, , , , , Bisphosphonate-Related Osteonecrosis of the Mandible and Maxilla, Journal of Computer Assisted Tomography, 2009, 33, 3, 449
- 114, , , , Bisphosphonate-related osteonecrosis: genetic and acquired risk factors, Oral Diseases, 2009, 15, 6Direct Link:
- 115, , Bisphosphonates as adjuvant therapy in multimodal pain management, memo - Magazine of European Medical Oncology, 2009, 2, 3, 161
- 116
- 117, , , , , , Bone Metastases From Advanced Cancers, Clinical Journal of Oncology Nursing, 2009, 13, 6, 701
- 118
- 119, , , , , Comparación de dos fórmulas de cálculo de filtrado glomerular en la dosificación del ácido zoledrónico, Farmacia Hospitalaria, 2009, 33, 1, 26
- 120, , , , , Comparison of two formulae for the calculation of glomerular filtration in the dosage of zoledronic acid, Farmacia Hospitalaria (English Edition), 2009, 33, 1, 26
- 121, , Effect of bisphosphonates on pain and quality of life in patients with bone metastases, Nature Clinical Practice Oncology, 2009, 6, 3, 163
- 122, , , , Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer, European Journal of Cancer Care, 2009, 18, 6Direct Link:
- 123, , , , Extended Use of Intravenous Bisphosphonate Therapy for the Prevention of Skeletal Complications in Patients with Cancer, Cancer Investigation, 2009, 27, 10, 984
- 124
- 125, , , , Management of Complications in Multiple Myeloma, Seminars in Hematology, 2009, 46, 2, 176
- 126, , , , , Management of complications of androgen deprivation therapy in the older man, Critical Reviews in Oncology/Hematology, 2009, 70, 3, 235
- 127, , , , Multiple Myeloma Presenting as Mandibular Ill-Defined Radiolucent Lesion With Numb Chin Syndrome: A Case Report, Journal of Oral and Maxillofacial Surgery, 2009, 67, 9, 1991
- 128, , , , , , , , , , , Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment, Internal Medicine Journal, 2009, 39, 5Direct Link:
- 129
- 130, , , Pathogenesis and management of myeloma bone disease, Expert Review of Hematology, 2009, 2, 4, 385
- 131, , , Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates, BJU International, 2009, 104, 11Direct Link:
- 132, Preserving functional independence in elderly patients with cancer-associated bone disease: the role of zoledronic acid, Aging Health, 2009, 5, 2, 151
- 133, , , Radiotherapy in palliative treatment of painful bone metastases, Radiology and Oncology, 2009, 43, 4, 213
- 134, , , , , , , Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis, Medical Oncology, 2009, 27, 2, 224
- 135
- 136, , , , , , , , , The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis, International Journal of Cancer, 2009, 125, 7Direct Link:
- 137, , The Pharmacological Management of Skeletal-Related Events from Metastatic Tumors, Orthopedics, 2009, 32, 3, 188
- 138, , , , , , , , , , , , , , , The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network, Annals of Oncology, 2009, 20, 8, 1303
- 139, , , , , , , , , , , , , , , , , , , , , , Third consensus on medical treatment of metastatic breast cancer, Annals of Oncology, 2009, 20, 11, 1771
- 140
- 141, , , , , , , , , , , , , , Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study, Supportive Care in Cancer, 2009, 18, 6, 691
- 142, , , , , , A CASE REPORT OF RECTAL CANCER WHICH CAUSED A HUGE BONE METASTASIS, Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2008, 69, 6, 1456
- 143, , , , , , , , , , , , A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma, Cancer, 2008, 113, 7Direct Link:
- 144, Bisphosphonates et traitements innovants de l’ostéolyse tumorale, Revue du Rhumatisme, 2008, 75, 6, 511
- 145, , , , , , , Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions, Cancer Treatment Reviews, 2008, 34, 7, 629
- 146, , , , , , , , Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both smad and P38 pathways, Journal of Cellular Biochemistry, 2008, 103, 5Direct Link:
- 147
- 148, , , Current and future treatments of bone metastases, Expert Opinion on Emerging Drugs, 2008, 13, 4, 609
- 149, , , , , , , , Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients, Expert Opinion on Pharmacotherapy, 2008, 9, 8, 1351
- 150, , , , , , , , , Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan, Annals of Oncology, 2008, 20, 1, 137
- 151, , , Ibandronate in profile: drug characteristics and clinical efficacy, Expert Opinion on Drug Metabolism & Toxicology, 2008, 4, 7, 941
- 152, Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management, Expert Opinion on Drug Safety, 2008, 7, 4, 491
- 153, , , , , , , , Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid, Cancer, 2008, 113, 1Direct Link:
- 154, , Novel targets for and mechanisms of bone metastasis: Meeting report from skeletal complications of malignancy V, IBMS BoneKEy, 2008, 5, 8, 297
- 155, , , , , Pharmacotherapy of bone metastases in breast cancer patients, Expert Opinion on Pharmacotherapy, 2008, 9, 6, 937
- 156, , , , , , , , , , , Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues, Breast Cancer Research and Treatment, 2008, 124, 3, 745
- 157, , , , , , , , , Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study, Annals of Oncology, 2008, 19, 7, 1266
- 158, , , , , , , , , Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review, Supportive Care in Cancer, 2008, 17, 6, 719
- 159, , Side effects and pharmaceutical company bias: adverse event reporting in cancer supportive and palliative care trials, Expert Opinion on Investigational Drugs, 2008, 17, 12, 1787
- 160, , Spinal cord compression in cancer patients: Review of diagnosis and treatment, Current Oncology Reports, 2008, 10, 1, 78
- 161, , , , , , Successful treatment of SAPHO syndrome with an oral bisphosphonate, Rheumatology International, 2008, 29, 6, 713
- 162, Treatment of breast cancer with bone metastasis: bisphosphonate treatment — current and future, International Journal of Clinical Oncology, 2008, 13, 1, 18
- 163
- 164
- 165
- 166
- 167
- 168
- 169, , , , , , , A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma, Leukemia, 2007, 21, 7, 1545
- 170, , , A multicenter phase II trial of domestic product of zoledronic acid in the treatment of malignant hypercalcemia, The Chinese-German Journal of Clinical Oncology, 2007, 6, 4, 393
- 171, , , , , , , , , A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid, Skeletal Radiology, 2007, 36, 12, 1121
- 172, Bisphosphonates in Advanced Malignant Disease, Clinical Reviews in Bone and Mineral Metabolism, 2007, 5, 3, 172
- 173, , , , , , , Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study, Supportive Care in Cancer, 2007, 15, 10, 1177
- 174, , , , , , , Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission, British Journal of Haematology, 2007, 137, 5Direct Link:
- 175, Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review, Supportive Care in Cancer, 2007, 15, 11, 1243
- 176
- 177, , , , , Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer, European Journal of Cancer Care, 2007, 16, 6Direct Link:
- 178, , , Local effects of malignancy on bone, Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 6, 436
- 179, , , Non-inferiority trial design for recurrent events, Statistics in Medicine, 2007, 26, 25Direct Link:
- 180, Optimal management of metastatic bone disease, European Journal of Oncology Nursing, 2007, 11, S32
- 181, , Osteonecrosis and Bisphosphonates in Oral and Maxillofacial Surgery, Oral and Maxillofacial Surgery Clinics of North America, 2007, 19, 2, 199
- 182, , , , , , Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature, European Journal of Internal Medicine, 2007, 18, 5, 417
- 183
- 184, , , , , , Pathologic fractures correlate with reduced survival in patients with malignant bone disease, Cancer, 2007, 110, 8Direct Link:
- 185, , , , Predictive value of osteocalcin and β-CrossLaps in metastatic breast cancer, Clinical Biochemistry, 2007, 40, 16-17, 1201
- 186, , Recent Developments in Bisphosphonate Therapy, Seminars in Arthritis and Rheumatism, 2007, 37, 1, 1
- 187, Role of the nurse in preserving patients’ independence, European Journal of Oncology Nursing, 2007, 11, S38
- 188, , , , Skeletal metastases in non-small cell lung cancer: A retrospective study, Lung Cancer, 2007, 57, 2, 229
- 189, , Supportive care in multiple myeloma, Best Practice & Research Clinical Haematology, 2007, 20, 4, 817
- 190, , , , , , , , The Effect of Alendronate, Risedronate, and Raloxifene on Renal Functions, Based on the Cockcroft and Gault Method, in Postmenopausal Women, Renal Failure, 2007, 29, 4, 471
- 191, , , The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma, Leukemia, 2007, 21, 9, 1875
- 192
- 193, , , Treatment Strategies in Elderly Patients with Multiple Myeloma, Drugs & Aging, 2007, 24, 10, 829
- 194, , , , , , , Zoledronic Acid Treatment at Home: Safety Data from an Observational Prospective Trial, Journal of Palliative Medicine, 2007, 10, 2, 352
- 195, Zoledronic acid: clinical potential beyond the prevention of skeletal complications in patients with cancer, Therapy, 2007, 4, 3, 241
- 196, , , , , , , , A Novel Case of Bisphosphonate-Related Osteonecrosis of the Torus Palatinus in a Patient with Metastatic Breast Cancer, Oncology, 2006, 71, 3-4, 306
- 197, , , , , , , A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats, Bone, 2006, 39, 4, 787
- 198
- 199, , Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease, Drugs, 2006, 66, 16, 2031
- 200, Bisphosphonates for malignancy-related bone disease: current status, future developments, Supportive Care in Cancer, 2006, 14, 5, 408
- 201, , , , , , Fracture risk in patients with monoclonal gammopathy of undetermined significance, British Journal of Haematology, 2006, 135, 1Direct Link:
- 202, , , Guidelines on the diagnosis and management of multiple myeloma 2005, British Journal of Haematology, 2006, 132, 4Direct Link:
- 203, , , , , , , Impact of Skeletal Complications on Total Medical Care Costs among Patients with Bone Metastases of Lung Cancer, Journal of Thoracic Oncology, 2006, 1, 6, 571
- 204, , , , Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results, European Journal of Cancer Care, 2006, 15, 3Direct Link:
- 205, , , , , Long-Term Safety of Intravenous Ibandronic Acid for Up to 4 Years in??Metastatic Breast Cancer, Clinical Drug Investigation, 2006, 26, 6, 315
- 206, , , , , , , Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates, Nature Clinical Practice Oncology, 2006, 3, 6, 325
- 207, , Myeloma bone disease and treatment options, European Journal of Cancer, 2006, 42, 11, 1554
- 208, Optimizing patient therapy: the role of bone markers?, Cancer Treatment Reviews, 2006, 32, 3
- 209, , , Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis, Urologic Oncology: Seminars and Original Investigations, 2006, 24, 1, 4
- 210
- 211, What do patients with metastatic bone pain need?, European Journal of Cancer Supplements, 2006, 4, 8, 1
- 212, , , , , Zoledronic acid in the management of metastatic bone disease, Expert Opinion on Biological Therapy, 2006, 6, 12, 1333
- 213
- 214
- 215, , , , Approaches to managing bone metastases from breast cancer: The role of bisphosphonates, Cancer Treatment Reviews, 2005, 31, 4, 303
- 216
- 217, , , , , , , , , , , , , , , , , , , Autologous stem cell transplantation in myeloma: the St James’s Hospital experience, 1997–2003, Irish Journal of Medical Science, 2005, 174, 2, 26
- 218, , , , Bisphosphonates and bone metastases: current status and future directions, Expert Review of Anticancer Therapy, 2005, 5, 2, 295
- 219, , Bisphosphonates for Metastatic Bone Pain, Journal of Pain and Palliative Care Pharmacotherapy, 2005, 19, 3, 61
- 220
- 221, Comment on ‘morbidity measures in the presence of recurrent composite endpoints’, Scott M, Möcks J, Givens S, et al. Pharmaceutical Statistics 2003; 2(1):39–49, Pharmaceutical Statistics, 2005, 4, 1Direct Link:
- 222, , , , , , , Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy, Supportive Care in Cancer, 2005, 13, 12, 975
- 223, , , , , , , Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom, Clinical Therapeutics, 2005, 27, 8, 1295
- 224, , , , Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK, Current Medical Research and Opinion, 2005, 21, 5, 805
- 225, , , , , Economic Evaluation of Zoledronic Acid Versus Pamidronate for the Prevention of Skeletal-Related Events in Metastatic Breast Cancer and Multiple Myeloma, American Journal of Clinical Oncology, 2005, 28, 1, 8
- 226, , Hypercalcemia in Breast Cancer: An Echo of Bone Mobilization During Lactation?, Journal of Mammary Gland Biology and Neoplasia, 2005, 10, 2, 157
- 227, Ibandronate: efficacy in the treatment of metastatic bone disease, Future Oncology, 2005, 1, 5, 593
- 228, Management of bone metastases in breast cancer, Current Treatment Options in Oncology, 2005, 6, 2, 161
- 229
- 230
- 231, New therapeutic agents for the treatment of bone diseases, Expert Opinion on Biological Therapy, 2005, 5, 6, 817
- 232, , , , Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma, Internal Medicine Journal, 2005, 35, 12Direct Link:
- 233, , , Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines, International Journal of Radiation Oncology*Biology*Physics, 2005, 61, 2, 535
- 234, , The Role of Bisphosphonates in the Management of Advanced Cancer with a Focus on Non-Small-Cell Lung Cancer, Oncology, 2005, 68, 1, 18
- 235, , , , , , , , , Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration, British Journal of Cancer, 2005, 92, 10, 1869
- 236, Zoledronic acid: past, present and future roles in cancer treatment, Future Oncology, 2005, 1, 2, 149
- 237, Zoledronic acid: pharmacologic profile of a potent bisphosphonate, Journal of Organometallic Chemistry, 2005, 690, 10, 2439
- 238, , Bisphosphonates in the treatment of skeletal metastases, Seminars in Oncology, 2004, 31, 59
- 239, , , Bisphosphonates to Prevent Skeletal Morbidity in Patients with Lung Cancer with Bone Metastases, Clinical Lung Cancer, 2004, 5, 5, 267
- 240, , Clinical Endpoints for Assessing Bisphosphonate Efficacy in the Prevention of Skeletal Complications of Bone Metastases, European Urology Supplements, 2004, 3, 5, 34
- 241, , , Clinical trials and evidence-based medicine for metastatic spine disease, Neurosurgery Clinics of North America, 2004, 15, 4, 549
- 242, E15. Treatment of metastatic bone disease, European Journal of Cancer Supplements, 2004, 2, 3, 32
- 243, Efficacy and safety of ibandronate in the treatment of neoplastic bone disease, Expert Opinion on Pharmacotherapy, 2004, 5, 11, 2341
- 244, Efficacy of Zoledronic Acid in the Treatment of Bone Metastases Secondary to Renal Cell Carcinoma, European Urology Supplements, 2004, 3, 5, 40
- 245, Future Directions for Zoledronic Acid and New Agents for the Treatment of Bone Metastases, European Urology Supplements, 2004, 3, 5, 55
- 246
- 247, , , Ibandronate reduces skeletal morbidity in patients with breast cancer, Seminars in Oncology, 2004, 31, 64
- 248, , Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease, Expert Review of Anticancer Therapy, 2004, 4, 6, 991
- 249, Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy, Seminars in Oncology, 2004, 31, 23
- 250, , , , , , , , Primary Cutaneous Plasmacytoma after Rejection of a Transplanted Kidney: Case Report and Review of the Literature, International Journal of Hematology, 2004, 80, 4, 361
- 251, , , Profiling the safety and tolerability of bisphosphonates, Seminars in Oncology, 2004, 31, 73
- 252, , Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy, Supportive Care in Cancer, 2004, 12, 12, 877
- 253, , , Review of ibandronate in the treatment of metastatic bone disease: Experience from phase III trials, Clinical Therapeutics, 2004, 26, 12, 1947
- 254, , , , , , Short-term safety assessment in the use of intravenous zoledronic acid in children, The Journal of Pediatrics, 2004, 145, 5, 701
- 255
- 256
- 257, , , Bisphosphonates and other bone agents for breast cancer, The Cochrane Library,Direct Link:
- 258, , , Bisphosphonates for breast cancer, The Cochrane Library,Direct Link:
- 259, , , , , , , , Bisphosphonates in multiple myeloma, The Cochrane Library,Direct Link:
- 260, , , , , , , , Bisphosphonates in multiple myeloma: a network meta-analysis, The Cochrane Library,Direct Link: